Zobrazeno 1 - 10
of 4 113
pro vyhledávání: ''
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Elotuzumab plus pomalidomide/dexamethasone (E-Pd) demonstrated efficacy and safety in relapsed and refractory multiple myeloma (RRMM). The clinical pharmacology of elotuzumab [± lenalidomide/dexamethasone (Ld)] was characterized previously.
Autor:
Akihito Tsuji, Dai Manaka, Masato Kataoka, Masashi Fujii, Masahiro Takeuchi, Takanori Watanabe, Masato Nakamura, Wataru Ichikawa, Hiroshi Matsuoka
Publikováno v:
Targeted Oncology. 16:753-760
Regorafenib and trifluridine/tipiracil are standard third-line chemotherapies for colorectal cancer patients, but their efficacy is limited. Anti-epidermal growth factor receptor antibody rechallenge has been reported to be promising for patients who
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Raphael Teipel, Susanne Quick, Stephan Richter, Holger Knoth, Theresa Kretschmann, Frank Kroschinsky, Christoph Röllig, Ekaterina Balaian, Nael Alakel, Martin Bornhäuser, Sandra Heuschkel, Malte von Bonin, Simone von Bonin
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose High-dose methotrexate (HDMTX)-associated acute kidney injury with delayed MTX clearance has been linked to an excess in MTX-induced toxicities. Glucarpidase is a recombinant enzyme that rapidly hydrolyzes MTX into non-toxic metabolites. The
Autor:
Amy E. DeZern, Bhagirathbhai Dholaria, Richard J. Jones, Vikas Gupta, Siddharth Kunte, Asad Bashey, Aaron T. Gerds, Anurag K. Singh, Michael R. Grunwald, Roni Tamari, Michael Ozga, Hany Elmariah, Auro Viswabandya, Lisa Rybicki, Alla Keyzner, Madiha Iqbal, Sameem Abedin, Tania Jain
Publikováno v:
Leukemia
We report the results from a multicenter retrospective study of 69 adult patients who underwent haploidentical blood or marrow transplantation (haplo-BMT) with post-transplantation cyclophosphamide (PTCy) for chronic phase myelofibrosis. The median a
Autor:
Joanne M O'Rourke, Nekisa Zakeri, Yuk Ting Ma, Tu Vinh Luong, Sam Khan, Chinenye Iwuji, Essam Hashem, Dominic Yu, Alexa Childs, Richard A Hubner, Tim Meyer, Joanna L Connor, Daniel H. Palmer, Kimberley Hockenhull, Chiara Braconi, Suzanne Darby, Daniel Swinson, Paul Ross, Tom Roques
Publikováno v:
British Journal of Cancer
Background Advanced hepatocellular carcinoma (HCC) is commonly diagnosed using non-invasive radiological criteria (NIRC) defined by the European Association for the Study of the Liver or the American Association for the Study of Liver Diseases. In 20
Autor:
Michael Thomas, Maria Palmisano, Mark Thomas, Sekhar Surapaneni, Yongjun Xue, Mary Liu, Simon Zhou, Rebecca N. Wood-Horrall, Gopal Krishna, Liangang Liu, Leonidas N Carayannopoulos, Ken Ogasawara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:941-952
Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and mul
Publikováno v:
Leukemia
Data from 1661 consecutive subjects with chronic-phase chronic myeloid leukemia (CML) receiving initial imatinib (n = 1379) or a 2nd-generation tyrosine-kinase inhibitor (2G-TKI; n = 282) were interrogated to determine whether the Sokal or European T
Autor:
Milan Hora, Tomas Buchler, Jan Filipovský, Pavel Ostasov, Ivan Trávníček, Barbora Bendová, Jan Šustr, Jindřich Fínek, Aneta Rozsypalova, Ondřej Šorejs, Ondřej Fiala
Publikováno v:
Targeted Oncology. 16:643-652
Patients with metastatic renal cell carcinoma (mRCC) are often elderly and have various comorbidities, including cardiovascular diseases. Although these patients have extensive co-exposure to targeted therapy and cardiovascular drugs, the impact of t
Autor:
Agnieszka Paradowska-Gorycka, Ewa Walczuk, Katarzyna Romanowska-Próchnicka, Malgorzata Jaronczyk, L N Sivitskaya, Tomasz Wysocki, Jakub Lach, Anna Wajda, Barbara Stypinska, Danat Yermakovich
Publikováno v:
The Pharmacogenomics Journal
Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis. Nevertheless, MTX resistance is quite a common issue in clinical practice. There are some premises that aryl hydrocarbon receptor (AhR) gene battery may take part in MTX metabolis